Management team
Neil Smith B.Sc.
CEO
Neil has extensive senior General Management and Marketing experience in the international Medical Device Industry. He has considerable expertise in launching new products and therapies in international markets. Neil has a degree in Chemistry from Aston University in the UK and Business School training from INSEAD (CEDEP) in France. Neil has previous Medical Device experience in Dialysis and IV Therapy and previous employers include Baxter and Kendall McGaw.
Prior to joining Probe Neil was CEO of Healthline Products Ltd, responsible for the UK and Europe.
Paul Jenkinson BSc, ACA, MSI
Finance Director
Paul qualified in 1994 as a Chartered Accountant with Deloitte & Touche. He then moved into corporate finance and spent three years raising funds for early stage technology companies. He then spent a further two years working on larger buy-outs, mergers and acquisitions and corporate disposals for private and public companies. In 1999 Paul become Finance Director of a software company and subsequently floated it on OFEX. In 2001 Paul become Finance Director of an AIM quoted software company. From 2002 Paul was Finance Director for a number of venture capital backed companies. Paul joined the board of Probe Scientific as Finance Director in 2005.
Mark O’Connell MIBiol CBiol (London), PhD (London)
Co-founder of Probe Scientific / Research and Development Director
As an Analyst at the “Poisons Unit”, Guy’s Hospital, London, from 1980 to 86, Mark recognised the problems associated with diagnostics using conventional blood sampling. While studying for his PhD at the Institute of Neurology, London, he began using what was then the novel technique of brain microdialysis. Mark pioneered the application of clinical microdialysis initially at the National Hospital for Neurology and Neurosurgery, London , where he was Principal Biochemist from 1991–1995, and then as Senior Clinical Scientist until 2005 at Addenbrooke’s Hospital, University of Cambridge. His knowledge and know-how helped Cambridge establish an international reputation as leaders in this field. In 1993, he began the novel application of intravenous microdialysis for drug monitoring in patients publishing the results of this 'proof-of-principle' work in the British Journal of Clinical Pharmacology. Mark is an international speaker and an author of over 50 scientific and medical papers.